Erythropoietin (EPO) is a neuroprotective
cytokine in models of ischemic and
nervous system injury, where it reduces neuronal apoptosis and inflammatory
cytokines and increases neurogenesis and angiogenesis. EPO also improves cognition in healthy volunteers and schizophrenic patients. We studied the effect of EPO administration on the gene-expression profile in the ischemic cortex of rats after
cerebral ischemia at early time points (2 and 6 h). EPO treatment up-regulated genes already increased by
ischemia. Hierarchical clustering and analysis of overrepresented functional categories identified genes implicated in synaptic plasticity-
Arc,
BDNF, Egr1, and Egr2, of which Egr2 was the most significantly regulated. Up-regulation of
Arc,
BDNF, Dusp5, Egr1, Egr2, Egr4, and Nr4a3 was confirmed by quantitative PCR. We investigated the up-regulation of Egr2/Krox20 further because of its role in neuronal plasticity. Its elevation by EPO was confirmed in an independent in vivo experiment of
cerebral ischemia in rats. Using the rat
neuroblastoma B104, we found that wild-type cells that do not express EPO receptor (EPOR) do not respond to EPO by inducing Egr2. However, EPOR-expressing B104 cells induce Egr2 early upon incubation with EPO, indicating that Egr2 induction is a direct effect of EPO and that EPOR mediates this effect. Because these changes occur in vivo before decreased inflammatory
cytokines or neuronal apoptosis is evident, these findings provide a molecular mechanism for the neuroreparative effects of
cytokines and suggest a mechanism of neuroprotection by which promotion of a
plastic phenotype results in decreased
inflammation and neuronal death.